Reneo Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
Reneo Pharmaceuticals, Inc. carries a market capitalization of 60.84M, placing it among publicly traded companies globally. Its enterprise value stands at 430.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 60.84M |
| Enterprise Value | 430.75M |
Share Statistics
Reneo Pharmaceuticals, Inc. currently has 33.42M shares outstanding.
| Shares Outstanding | 33.42M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.18 |
| P/TBV Ratio | 6.59 |
| P/FCF Ratio | -7.64 |
| P/OCF Ratio | -7.64 |
Financial Position
Reneo Pharmaceuticals, Inc. maintains a current ratio of 57.86, meaning it holds 57.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 57.86 |
| Quick Ratio | 56.88 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -49.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Reneo Pharmaceuticals, Inc.'s stock has declined approximately -76.66667% over the past 52 weeks. The 50-day moving average sits at 14.92, while the 200-day moving average is 16.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | -76.66667% |
| 50-Day Moving Average | 14.92 |
| 200-Day Moving Average | 16.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -61.71M, while operating income came in at -61.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -61.82M |
| Pretax Income | -56.54M |
| Net Income | -56.54M |
| EBITDA | -61.71M |
| EBIT | -61.82M |
| Earnings Per Share (EPS) | -1.69 |
Balance Sheet
Reneo Pharmaceuticals, Inc. holds 76.67M in cash and equivalents against 823,000.00 in total debt, resulting in a net debt position of -35.97M. Total book value stands at -232.26M, with working capital of 76.64M providing operational flexibility.
| Cash & Cash Equivalents | 76.67M |
| Total Debt | 823,000.00 |
| Net Debt | -35.97M |
| Equity (Book Value) | -232.26M |
| Book Value Per Share | -6.92 |
| Working Capital | 76.64M |
Cash Flow
Reneo Pharmaceuticals, Inc. produced -66.34M in operating cash flow over the past twelve months. After subtracting -46,000.00 in capital expenditures, free cash flow totaled -66.39M - equivalent to -1.98 per share.
| Operating Cash Flow | -66.34M |
| Capital Expenditures | -46,000.00 |
| Free Cash Flow | -66.39M |
| FCF Per Share | -1.98 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.80 |
| FCF Yield | -13.09 |
Stock Splits
Reneo Pharmaceuticals, Inc.'s most recent stock split took place on October 7, 2024 with a 10:1 split ratio.
| Last Split Date | 10/7/2024 |
| Split Ratio | 10:1 |
Scores
Reneo Pharmaceuticals, Inc. posts an Altman Z-Score of 158.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 158.93 |